Paper39192059
Development of 52Mn Labeled Trastuzumab for Extended Time Point PET Imaging of HER2.
Omweri JM and 6 others. Mol Imaging Biol, 2024. Cited by 9 papers, by iCite.
Cite this record
ConductScience Library. Development of 52Mn Labeled Trastuzumab for Extended Time Point PET Imaging of HER2. Papers, record 39192059. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39192059
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Trastuzumab | Major topic |
| Positron-Emission Tomography | Major topic |
| Erb-b2 Receptor Tyrosine Kinases | Major topic |
| Manganese | Major topic |
| Animals | |
| Humans | |
| Cell Line, Tumor | |
| Female | |
| Tissue Distribution | |
| Mice | |
| Mice, Nude | |
| Isotope Labeling |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P30 CA013148 | NCI NIH HHS | United States | P30CA013148 | PubMed | NIH RePORTER |
| DESC0021269 | Office of Science | PubMed | PubMed |
References55
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28872549 | 89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2-Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer. | Clin Nucl Med | 2017 | https://conductscience.org/library/papers/28872549 | PubMed |
| 2 | 27151988 | Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT. | J Nucl Med | 2016 | https://conductscience.org/library/papers/27151988 | PubMed |
| 3 | 38154167 | Chelation chemistry of manganese-52 for PET imaging applications. | Nucl Med Biol | 2024 | https://conductscience.org/library/papers/38154167 | PubMed |
| 4 | 33948375 | ImmunoPET of the differential expression of CD146 in breast cancer. | Am J Cancer Res | 2021 | https://conductscience.org/library/papers/33948375 | PubMed |
| 5 | 22998840 | PET imaging with ⁸⁹Zr: from radiochemistry to the clinic. | Nucl Med Biol | 2013 | https://conductscience.org/library/papers/22998840 | PubMed |
| 6 | 37385676 | Immuno-PET Detects Antibody-Drug Potency on Coadministration with Statins. | J Nucl Med | 2023 | https://conductscience.org/library/papers/37385676 | PubMed |
| 7 | 31562219 | Total-Body PET and Highly Stable Chelators Together Enable Meaningful 89Zr-Antibody PET Studies up to 30 Days After Injection. | J Nucl Med | 2020 | https://conductscience.org/library/papers/31562219 | PubMed |
| 8 | 15289297 | Preclinical characterisation of 111In-DTPA-trastuzumab. | Br J Pharmacol | 2004 | https://conductscience.org/library/papers/15289297 | PubMed |
| 9 | 34857660 | Use of 64Cu-DOTA-Trastuzumab PET to Predict Response and Outcome of Patients Receiving Trastuzumab Emtansine for Metastatic Breast Cancer: A Pilot Study. | J Nucl Med | 2022 | https://conductscience.org/library/papers/34857660 | PubMed |
| 10 | 25058168 | Evaluation of (89)Zr-pertuzumab in Breast cancer xenografts. | Mol Pharm | 2014 | https://conductscience.org/library/papers/25058168 | PubMed |
| 11 | 20660376 | 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. | J Nucl Med | 2010 | https://conductscience.org/library/papers/20660376 | PubMed |
| 12 | 30676778 | Imaging of HER2 with [89Zr]pertuzumab in Response to T-DM1 Therapy. | Cancer Biother Radiopharm | 2019 | https://conductscience.org/library/papers/30676778 | PubMed |
| 13 | 30151358 | Effect of the Nature of Donor Atoms on the Thermodynamic, Kinetic and Relaxation Properties of Mn(II) Complexes Formed With Some Trisubstituted 12-Membered Macrocyclic Ligands. | Front Chem | 2018 | https://conductscience.org/library/papers/30151358 | PubMed |
| 14 | 38733556 | Good practices for 89Zr radiopharmaceutical production and quality control. | EJNMMI Radiopharm Chem | 2024 | https://conductscience.org/library/papers/38733556 | PubMed |
| 15 | 37552575 | Evaluation of [89Zr]Zr-DFO-2Rs15d Nanobody for Imaging of HER2-Positive Breast Cancer. | Mol Pharm | 2023 | https://conductscience.org/library/papers/37552575 | PubMed |
| 16 | 20111600 | Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab. | PLoS One | 2010 | https://conductscience.org/library/papers/20111600 | PubMed |
| 17 | 29357745 | Targeting HER2 in Nuclear Medicine for Imaging and Therapy. | Mol Imaging | 2018 | https://conductscience.org/library/papers/29357745 | PubMed |
| 18 | 26598545 | Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. | Ann Oncol | 2016 | https://conductscience.org/library/papers/26598545 | PubMed |
| 19 | 31548601 | HER2-targeted therapies - a role beyond breast cancer. | Nat Rev Clin Oncol | 2020 | https://conductscience.org/library/papers/31548601 | PubMed |
| 20 | 23736785 | (89)Zr, a radiometal nuclide with high potential for molecular imaging with PET: chemistry, applications and remaining challenges. | Molecules | 2013 | https://conductscience.org/library/papers/23736785 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42708148 | Radiocopper in BCMA-targeted immunotheranostics of myeloma. | Theranostics | 2026 | https://conductscience.org/library/papers/42708148 | PubMed |
| 42356507 | Emerging Theranostic Radiometals (149Tb, 44Sc, 52Mn, 203Pb, 55Co)-Decay Diversity, Production Landscape, and Translational Imaging. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/42356507 | PubMed |
| 42120551 | Tellurium-118 as a novel radionuclide for long-term positron emission tomography. | Sci Rep | 2026 | https://conductscience.org/library/papers/42120551 | PubMed |
| 41901362 | Enhanced Tumor-to-Background Contrast with [52Mn]Mn-BPPA-Bevacizumab VEGF-Targeted Immuno-PET in Cervical Cancer. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/41901362 | PubMed |
| 40365451 | HER2 expression in different cell lines at different inoculation sites assessed by [52Mn]Mn-DOTAGA(anhydride)-trastuzumab. | Pathol Oncol Res | 2025 | https://conductscience.org/library/papers/40365451 | PubMed |
| 40131608 | Highlight selection of radiochemistry and radiopharmacy developments by editorial board. | EJNMMI Radiopharm Chem | 2025 | https://conductscience.org/library/papers/40131608 | PubMed |
| 39768978 | Novel Molecular Classification of Breast Cancer with PET Imaging. | Medicina (Kaunas) | 2024 | https://conductscience.org/library/papers/39768978 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| ERBB2 | 2064 | PubTator's text mining | https://conductscience.org/library/genes/2064 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39192059
GET https://conductscience.org/api/papers/v1/39192059/references?page=2